China's 'Next New Three': AI, Robotics, and Innovative Drugs Reshape Global Pharma R&D Landscape
核心洞察
China's innovative drug sector has emerged as a core strategic industry alongside AI and robotics, collectively dubbed the "next new three" by the Minister of Science and Technology.
Outbound technology licensing transactions for Chinese innovative drugs (搜索) reached approximately $110 billion in the first half of 2026, with Chinese firms accounting for eight of the world's top 10 pharmaceutical licensing deals.
Chinese innovative drug companies are now exporting capabilities across the entire value chain, including target discovery, clinical transformation, and global registration, beyond finished medicine products.
China's innovative pharmaceutical sector has been formally recognized as one of the country's "next new three" core strategic industries, a designation that signals the nation's accelerating transition from manufacturing powerhouse to global innovation leader. Yin Hejun (搜索), China's Minister of Science and Technology, announced the designation at a recent policy briefing, placing innovative drugs (搜索) alongside artificial intelligence and robotics as the new growth drivers reshaping China's industrial and export landscape.
The "next new three" represents the latest evolution in China's decades-long industrial trajectory, following the "old three" of apparel, furniture, and home appliances, and the "new three" of electric vehicles, lithium batteries, and photovoltaic products. While the earlier phases centered on physical merchandise trade, the current wave focuses on exporting integrated technological capabilities and services.
Innovative Drugs (搜索) Surge in Global Deal-Making
The numbers underscore the sector's meteoric rise. In the first half of 2026, the disclosed potential total value of out-licensing deals for Chinese innovative drugs (搜索) reached approximately $110 billion. Chinese pharmaceutical enterprises accounted for eight of the world's top 10 pharmaceutical licensing deals during this period, a striking demonstration of the country's growing influence in global drug development.
This represents a fundamental shift in how Chinese pharmaceutical innovation reaches global markets. Rather than simply exporting finished medicine products, Chinese innovative drug companies now export capabilities across the entire value chain—including target discovery, clinical transformation, and global registration. The model has evolved into deep, mutually integrated R&D partnerships between Chinese drug developers and multinational pharmaceutical firms.
From Manufacturing Hub to Innovation Source
The emergence of innovative medicines as a strategic pillar reflects what officials describe as China's transition "from a global manufacturing hub into a global source of innovation." The country's competitive edge is increasingly measured by its ability to define new products, open new frontiers, set new standards, and integrate global resources through continuous innovation.
This transformation is supported by broader trade data. From January to May 2026, China's total services trade volume rose 6 percent year-on-year, with exports of knowledge-intensive services surging 12.2 percent—highlighting the improved competitiveness of China's services exports and the optimized structure of foreign trade.
Global Impact and Accessibility
Multiple drugs independently developed in China have entered international markets, bringing new therapeutic options to patients worldwide. The trend mirrors what occurred in photovoltaics and electric vehicles, where Chinese innovation dramatically lowered costs and expanded access. The "next new three" aims to ensure that cutting-edge technologies—including advanced medical capabilities—are accessible to developing nations at affordable costs, rather than remaining "limited-edition luxuries."
The policy emphasis on openness and inclusiveness has, according to Chinese officials, fueled a systemic leap in the country's capacity for indigenous innovation. As Yin Hejun (搜索)'s briefing underscored, these industries are emerging as new growth drivers focused on bolstering public well-being amid high-quality development, with innovative medicines playing a central role in that vision.